Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Despite the availability of effective anti-tuberculosis agents that exist to treat this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT) such as isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) is not uncommon and limit their use. There is no consensus on method of the reintroduction of anti-TB medications. The risk of reintroducing of a anti-TB medications could be hazardous. There are several differences between the guidelines from the ATS, BTS and the Task Force of the European Respiratory Society, the WHO and the International Union Against Tuberculosis and Lung Disease about the methods of reintroducing of anti-TB medications.

The investigators plan to do a prospective study to evaluate the outcome and safety of reintroduction of anti-TB medications after resolution of hepatitis during anti-TB treatment among TB patients in the investigators hospital.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Antitubercular Agents; Isoniazid; Pyrazinamide; Rifampin

Criteria

Inclusion Criteria:

• Hepatitis during anti-tuberculosis treatment

• Hold RMP, INH and PZA after hepatitis

• Age >= 18 years old

• HIV(-)

• T-bilirubin < 2.5 mg/dL

• No allergy to RMP, INH and PZA

Exclusion Criteria:

• Liver cirrhosis, child B or C

• Pregnancy and breast feeding

• Life expectation < 1 year